ArticlePloS one2021

Cabozantinib can block growth of neuroendocrine prostate cancer patient-derived xenografts by disrupting tumor vasculature.

Mark P Labrecque et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.